Compare USAC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USAC | DYN |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.9B |
| IPO Year | 2011 | 2020 |
| Metric | USAC | DYN |
|---|---|---|
| Price | $26.36 | $24.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $26.67 | ★ $37.00 |
| AVG Volume (30 Days) | 154.8K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 7.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $698,365,000.00 | N/A |
| Revenue This Year | $33.35 | N/A |
| Revenue Next Year | $6.09 | N/A |
| P/E Ratio | $31.25 | ★ N/A |
| Revenue Growth | ★ 19.51 | N/A |
| 52 Week Low | $21.85 | $8.88 |
| 52 Week High | $30.55 | $25.00 |
| Indicator | USAC | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 63.30 |
| Support Level | $25.99 | $16.47 |
| Resistance Level | $27.41 | $24.52 |
| Average True Range (ATR) | 0.78 | 1.46 |
| MACD | 0.08 | -0.11 |
| Stochastic Oscillator | 49.90 | 84.68 |
USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.